Literature DB >> 17374042

Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.

Stephanie S O'Malley1, Rajita Sinha, Carlos M Grilo, Christy Capone, Conor K Farren, Sherry A McKee, Bruce J Rounsaville, Ran Wu.   

Abstract

BACKGROUND: Despite important gender differences in drinking patterns, physiological effects of alcohol, and co-occurring psychiatric conditions, relatively little is known about the efficacy of naltrexone for the treatment of alcohol dependence in women. This study investigated the safety and efficacy of naltrexone in combination with Cognitive Behavioral Coping Skills Therapy (CBCST) in a sample of alcohol-dependent women, some with comorbid eating pathology.
METHODS: One hundred three women meeting DSM-IV criteria for alcohol dependence (29 with comorbid eating disturbances) were randomized to receive either naltrexone 50 mg or placebo for 12 weeks in addition to weekly group CBCST. Subjects were enrolled between October 1995 and December 2000 at an outpatient research clinic.
RESULTS: No significant differences were observed on the primary outcomes of time to first drinking day, time to first day of heavy drinking, or the percentage of participants who continued to meet the criteria for alcohol dependence. Secondary analyses revealed that naltrexone significantly delayed the time to the second (chi2=5.37, p=0.02) and third (chi2=4.35, p=0.04) drinking days among subjects who did not maintain abstinence from alcohol. Among those with eating disturbances, symptoms of eating pathology improved during treatment, but the effects did not differ according to medication condition.
CONCLUSION: When used in conjunction with CBCST, naltrexone did not significantly improve drinking outcomes in the overall sample of alcohol-dependent women. However, naltrexone may be of benefit to women who are unable to maintain total abstinence from alcohol. For women with concurrent eating pathology, participation in treatment for alcoholism may be associated with improvements in eating pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374042     DOI: 10.1111/j.1530-0277.2007.00347.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  31 in total

1.  Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence.

Authors:  Sharon Samet; Miriam C Fenton; Edward Nunes; Eliana Greenstein; Efrat Aharonovich; Deborah Hasin
Journal:  Addiction       Date:  2012-10-05       Impact factor: 6.526

2.  Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.

Authors:  Shelly F Greenfield; Helen M Pettinati; Stephanie O'Malley; Patrick K Randall; Carrie L Randall
Journal:  Alcohol Clin Exp Res       Date:  2010-07-20       Impact factor: 3.455

3.  The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

Authors:  Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

Review 4.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

5.  Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.

Authors:  Ralitza Gueorguieva; Ran Wu; Dennis Donovan; Bruce J Rounsaville; David Couper; John H Krystal; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2009-12-06       Impact factor: 4.492

6.  Alcohol dependence in women: Comorbidities can complicate treatment.

Authors:  Rebecca A Payne; Sudie E Back; Tara Wright; Karen Hartwell; Kathleen T Brady
Journal:  Curr Psychiatr       Date:  2009-06-01

7.  Clinical case discussion: binge eating disorder, obesity and tobacco smoking.

Authors:  Marney A White; Carlos M Grilo; Stephanie S O'Malley; Marc N Potenza
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

8.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Authors:  Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2018-09-21       Impact factor: 4.492

Review 9.  Medical treatment of alcohol dependence: a systematic review.

Authors:  Peter M Miller; Sarah W Book; Scott H Stewart
Journal:  Int J Psychiatry Med       Date:  2011       Impact factor: 1.210

Review 10.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.